title: [Brachytherapy of local prostatic carcinoma].
abstract: Brachytherapy of prostate cancer has become attractive in recent years in Germany. There are several radioactive sources available, which are physically different. Some of them are used as permanent or temporary implants. The permanent sources most frequently used are iodine 125, palladium 103, and gold 198. Iridium is a temporary implant. The techniques used in Germany are low-dose rate (LDR) and high-dose rate brachytherapy, which differ in dose distribution and patient population. The success of prostate cancer brachytherapy depends on patient selection and choosing the right source for the technique used. Best suited for LDR monotherapy is the low-risk patient with a prostate-specific antigen (PSA) level below 10 ng/ml, maximal tumor stage T2b, and a Gleason score of less than 7.
authors.affiliation: Urologische Klinik der Charité, Humboldt Universität, Campus Mitte, Schumannstrasse 20/21, 10098 Berlin. serdar.deger@charite.de
authors.forename: S
authors.initials: S
authors.lastname: Deger
authors.forename: D
authors.initials: D
authors.lastname: Böhmer
authors.forename: J
authors.initials: J
authors.lastname: Roigas
authors.forename: I
authors.initials: I
authors.lastname: Türk
authors.forename: V
authors.initials: V
authors.lastname: Budach
authors.forename: S A
authors.initials: SA
authors.lastname: Loening
mesh_terms: D001918:Brachytherapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000532:radiotherapy*; D011879:Radiotherapy Dosage